Illumina Tells Wall Street AgBio is ‘Significant’ for Arrays, Preps Dx Play | GenomeWeb
Illumina continues to see the agricultural biotechnology market as a “significant” growth opportunity for its microarray business, while it is positioning itself to enter the molecular diagnostics market, which it predicts will reach $20 billion within the next decade, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.